What ChondroFiller injection is — and what it is not

ChondroFiller® (also marketed as Liquid Cartilage™) is a CE-marked Class III medical device — an acellular, injectable type I collagen scaffold manufactured by Meidrix Biomedicals GmbH in Germany. Under ultrasound guidance, it is placed directly into a focal cartilage defect as an outpatient procedure, without general anaesthesia or theatre admission.

The confusion with other joint injections is understandable, but the distinctions matter. Hyaluronic acid lubricates the joint; corticosteroids reduce inflammation; stem-cell injections introduce biological cells. ChondroFiller contains none of these. It is a structural collagen matrix — cell-free by design — whose role is to occupy the defect space and recruit the patient's own progenitor cells from the surrounding tissue. This mechanism is called acellular matrix-induced chondrogenesis: the scaffold does not deliver cartilage, nor does it regrow cartilage directly. It supports the body's own repair processes by providing a 3D framework into which repair cells can migrate and mature over time.

Because no cartilage biopsy is needed before treatment, the entire pathway can be completed in a single outpatient appointment.

How the collagen scaffold works once it is injected

The product arrives in a two-chamber syringe: one chamber holds an ultrapure native type I collagen solution, the other a neutralising solution. A mixing adapter combines the two streams at the moment of delivery, so the material enters the defect freshly prepared and not yet set.

Once inside the joint, the shift in pH triggers gelation. Within approximately 3–5 minutes the fluid hardens into a dimensionally stable hydrogel, moulding itself to the precise shape and depth of the cavity — including irregular outlines — without bone-drilling or additional fixatives such as fibrin glue.

That stable matrix is the starting point, not the finished result. Over the following months, progenitor cells from the surrounding synovium and subchondral bone migrate into the 3D collagen framework, gradually differentiating and depositing new hyaline-like cartilage tissue. This regenerative process typically unfolds over roughly 6–24 months, with structural improvement visible on MRI as the scaffold matures.

ChondroFiller is not a permanent filler. As repair tissue forms and consolidates, the collagen scaffold is progressively resorbed by the body — what remains is new repair tissue occupying the space the defect once held, rather than a foreign implant staying in the joint indefinitely.

Who is suitable for ChondroFiller injection

The strongest candidates are patients with an isolated, focal cartilage defect — typically the result of a sporting injury, a single traumatic episode, or damage secondary to a meniscal tear — in an otherwise healthy joint. When the surrounding cartilage and the joint space as a whole are intact, the scaffold has a clear structural problem to address and a good biological environment in which to work.

Defect size is not a rigid barrier. Evidence covers lesions up to 6 cm², with smaller focal lesions representing the most straightforward indication. Joint coverage is broader than most patients expect: published experience includes the knee, hip, shoulder, ankle, elbow, hand, wrist, and foot, so the treatment is not a knee-only option. There is also no stated upper age limit; the relevant factor is the character of the defect itself, not the patient's date of birth.

When the outpatient injection route is not appropriate

The principal exclusion for the ultrasound-guided injection pathway is generalised severe osteoarthritis — specifically Kellgren–Lawrence Grade III or IV disease. At that stage, joint-space loss is diffuse rather than focal, and an injectable scaffold cannot compensate for widespread cartilage thinning across the joint surface. Patients with advanced imaging changes of this kind are better assessed for a surgical cartilage procedure or a joint management pathway rather than the injection route.

'Bone-on-bone' findings on a scan do not automatically rule out an assessment, but the severity and distribution of those changes matter considerably. A specialist review is the appropriate step to establish whether the defect is truly focal and contained — and therefore whether the injection route is indicated.

What happens at an ultrasound-guided ChondroFiller appointment

The appointment takes place in a clinic setting — no theatre admission, no general anaesthetic, and no surgical incisions. Patients typically arrive, are positioned comfortably, and the treatment is completed within a single outpatient visit.

The clinician begins by applying ultrasound imaging to the joint. Real-time scanning allows precise localisation of the defect and guides the needle into the correct position before any material is delivered — a step that matters because the scaffold needs to reach the cartilage cavity accurately to function as intended.

The injection itself uses the proprietary two-chamber syringe. As the plunger advances, the collagen solution and neutralising solution pass through a mixing adapter and combine in the needle at the moment of delivery — the two components meet inside the joint, not ahead of time. This means the material enters the defect in its unset, flowable state, conforming precisely to the cavity's shape and depth.

Once delivered, the collagen undergoes pH-triggered gelation and becomes a dimensionally stable hydrogel within approximately 3–5 minutes. Patients are typically observed briefly in the clinic before leaving the same day.

After the appointment, the specialist will advise on activity and weight-bearing modifications appropriate to the treated joint and defect location. Protocols vary by clinician and site; the principle during the early post-injection period is to allow the scaffold to stabilise undisturbed as the body's own repair process begins to get under way.

Clinical outcomes and the current state of evidence

Published data across four knee studies show a mean IKDC score improvement of approximately 30 points following ChondroFiller injection — a finding worth contextualising. The IKDC (International Knee Documentation Committee) scale rates knee function from 0 to 100; the Minimal Clinically Important Difference — the threshold at which a patient notices a real-world change — is 16.7 points. In the Jerosch et al. post-market clinical follow-up study, participants recorded a mean gain of 32.4 points, sustained at three years, reaching a mean score of 80. For patients starting from significant functional restriction, that magnitude of improvement typically corresponds to a meaningful return to everyday activity.

Structural evidence from MRI adds a second layer of confirmation. MOCART scoring measures how well a repair tissue fills the original defect and integrates with surrounding cartilage — a score above 80 indicates more than 80% fill and good tissue bonding. European studies report MOCART scores of 81.6–84.3 at follow-up, with one cohort showing progression from 65.3 at four weeks to 81.6 at one year, which aligns with the expected 6–24-month maturation window described in section two.

Across joint types, published series report that 70–85% of patients achieve meaningful symptom relief at three to five years. That figure is an aggregate: it is not currently stratified by defect size, patient age, or joint location, so it should be treated as a broad benchmark rather than a precise prediction for any individual presentation.

Contextual safety comparisons

Available comparisons suggest a favourable safety profile: complication rates approximate 0% and reoperation rates fall in the 3–8% range. For context, microfracture carries reoperation rates reported at up to 41% and produces fibrocartilage rather than hyaline-like repair tissue; ACI and MACI involve two surgical stages, with complication rates up to 17% and reoperation rates up to 37% in published series. These comparisons are contextual — no head-to-head randomised controlled trial of the injectable scaffold pathway against these alternatives has been published.

What the evidence does not yet show

Most supporting data come from prospective cohort studies and post-market follow-up programmes rather than large randomised controlled trials. Long-term data beyond five years remain limited. What is established — sustained functional gain, structural fill on MRI, and a low complication burden across a multi-joint evidence base — provides a reasonable foundation for a specialist discussion about suitability.

Finding a specialist who offers ChondroFiller injection

Finding a clinician with specific experience in injectable collagen scaffolds matters more than geography alone. ChondroFiller injection requires training in both the ultrasound-guided delivery technique and the patient selection criteria that determine whether the injectable route is appropriate — or whether a surgical approach would serve better. Relevant specialties include orthopaedic surgery, sport and exercise medicine, and musculoskeletal radiology.

Search MSK lists musculoskeletal specialists across the UK who offer ChondroFiller and related cartilage treatments, searchable by region and specialty — a practical starting point for identifying who practises this pathway locally.

For the assessment itself, bringing any existing MRI or imaging, a clear account of symptom duration and how function has changed, current activity level, and details of previous treatments gives the clinician what they need to determine whether a focal defect qualifies and which delivery route is appropriate for that specific presentation.